Genetically modified gamma delta t cells and methods of making and using
OwnerBeau Webber, Branden Moriarity +2inventors
InventorsBeau Webber, Branden Moriarity, Emily Joy Pomeroy, Patricia Nicole Claudio Vazquez
Life of this patent
Estimating the term…
Abstract
Provided herein are genome-edited γδ T cells that exhibit an increased capacity to kill cancer cells, methods of producing genome-edited γδ T cells, and methods of treating or preventing a condition by administering genome-edited γδ T cells to a subject in need thereof.
Claims20
A method for editing a genome of an activated γδ T cells, the method comprising
- a) providing a cell sample comprising T cells, T cell subsets and/or T cell progenitors;
- b) separating γδ T cells or a γδ T cell subset to thereby provide enriched γδ T cells;
- c) activating enriched γδ T cells using one or more modulatory agents to thereby provide activated γδ T cells;
- and
- d) genetically modifying the activated γδ T cells to thereby provide genetically modified T cells comprising one or more modifications in at least one gene selected from IL-17A (Interleukin 17A), DGKA (Diacylglycerol Kinase Alpha), DGKZ (Diacylglycerol Kinase Zeta), PD1 (programmed cell death 1), TRGC1 (T-cell Receptor Gamma Constant-1), TRGC2 (T-cell Receptor Gamma Constant-2), TRDC (T-cell Receptor Delta Constant), PD-L1 (Programmed death-ligand 1), and CISH (Cytokine-inducible SH2-containing protein), or any combination thereof.
A genome-edited γδ T cell comprising one or more mutations in a gene selected from IL-17A (Interleukin 17A), DGKA (Diacylglycerol Kinase Alpha), DGKZ (Diacylglycerol Kinase Zeta), PD1 (programmed cell death 1), TRGC1 (T-cell Receptor Gamma Constant-1), TRGC2 (T-cell Receptor Gamma Constant-2), TRDC (T-cell Receptor Delta Constant), PD-L1 (Programmed death-ligand 1), and CISH (Cytokine-inducible SH2-containing protein), or any combination thereof.
Dependencies are inferred from the claim text.